Author(s): Iketani T, Takazawa K, Yamashina A
Abstract Share this page
Abstract Central systolic blood pressure (C-SBP) has been shown to be a better predictor of cardiovascular risk than brachial SBP. In this study, the effects of eicosapentaenoic acid (EPA) on C-SBP were compared with pravastatin. Twenty-four patients with hyperlipidemia were assigned 13 to receive 1800 mg/day EPA (EPA group) and 11 to receive 10 mg/day pravastatin (pravastatin group) for 3 months. In the EPA group, there were no changes in the LDL-cholesterol level. However, the radial augmentation index (AI) and C-SBP decreased after treatment by 5.7\% (p < 0.01) and 8.7\% (p < 0.001), respectively. Moreover, systolic and diastolic brachial BPs decreased by 7.1\% and 8.0\%, respectively (p < 0.01 for both). In the pravastatin group, the LDL-cholesterol level decreased by 29.5\% (p < 0.001). However, there were no significant changes in brachial BP, AI and C-SBP between. These results suggested that EPA but not pravastatin may reduce cardiac afterload by reducing vascular reflected waves and lowering C-SBP. Copyright © 2012 Elsevier Ltd. All rights reserved.
This article was published in Prostaglandins Leukot Essent Fatty Acids
and referenced in Journal of Glycomics & Lipidomics